Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer
Jonathan P. Jarow(Center for Drug Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), V. Ellen Maher(United States Food and Drug Administration), Geoffrey Kim(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University)
Cited by 22
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k